Anaptysbio, Inc (ANAB): Capital Expenditures
$87.0K
Year ended 2025-12-31
$69.0K
Trailing 12 months to 2026-03-31
-37.6%
3-year compound annual growth
-31.3%
5-year compound annual growth
-9.6%
10-year compound annual growth
| Period ended | Capital Expenditures | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $87.0K | -75.7% | 2026-03-03, From 2025-01-01 |
| 2024-12-31 | $358.0K | -55.6% | 2026-03-03, From 2024-01-01 |
| 2023-12-31 | $807.0K | +125.4% | 2026-03-03, From 2023-01-01 |
| 2022-12-31 | $358.0K | -73.8% | 2025-02-27, From 2022-01-01 |
| 2021-12-31 | $1.37M | +140.1% | 2024-03-11, From 2021-01-01 |
| 2020-12-31 | $569.0K | -29.3% | 2023-03-01, From 2020-01-01 |
| 2019-12-31 | $805.0K | -24.3% | 2022-03-07, From 2019-01-01 |
| 2018-12-31 | $1.06M | +266.6% | 2021-02-25, From 2018-01-01 |
| 2017-12-31 | $290.0K | +480.0% | 2020-03-02, From 2017-01-01 |
| 2016-12-31 | $50.0K | -79.0% | 2019-02-28, From 2016-01-01 |
| 2015-12-31 | $238.0K | n/a | 2018-03-05, From 2015-01-01 |
Capital Expenditures at similar companies
| Company | Year ended | Capital Expenditures | Change YoY |
|---|---|---|---|
| Anaptysbio, Inc (ANAB) | 2025-12-31 | $87.0K | -75.7% |
| Akebia Therapeutics, Inc. (AKBA) | 2025-12-31 | $291.0K | +781.8% |
| Puma Biotechnology, Inc. (PBYI) | 2025-12-31 | $71.0K | +26.8% |
| Keros Therapeutics, Inc. (KROS) | 2025-12-31 | $1.55M | -19.7% |
| Arcus Biosciences, Inc. (RCUS) | 2025-12-31 | $2.00M | -66.7% |
| IDEAYA Biosciences, Inc. (IDYA) | 2025-12-31 | $2.37M | -38.6% |
| Vanda Pharmaceuticals Inc. (VNDA) | 2025-12-31 | $998.0K | +103.7% |
| Schrodinger, Inc. (SDGR) | 2025-12-31 | $1.44M | -80.3% |
| Arvinas, Inc. (ARVN) | 2025-12-31 | $1.90M | +5.6% |
Compare ANAB, AKBA, PBYI, KROS side by side · Screen every company in Pharmaceutical Preparations ↗